Amorfix to present corporate overview at the Biotech Showcase 2013 conference

TSX: AMF

TORONTO, Jan. 4, 2013 /CNW/ - Amorfix Life Sciences Ltd., a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that Dr. Robert Gundel, Amorfix President and Chief Executive Officer, will present a general corporate overview and update at the Biotech Showcase conference at the Parc 55 Wyndham Hotel in San Francisco on January 8, 2013 at 9:30 a.m. Pacific time.

The Biotech Showcase conference is an international forum for providing private and public biotechnology and life sciences companies an opportunity to present and meet with investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences.

About Amorfix
Amorfix Life Sciences Ltd. (TSX:AMF) is an early-stage product development company developing therapeutic antibodies and diagnostics targeting misfolded protein diseases.  Amorfix utilizes its computational discovery platform, ProMIS™, to predict novel Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins.  Using this technology, Amorfix is developing novel antibody therapeutics and companion diagnostics for cancer and amyotrophic lateral sclerosis (ALS). In addition, Amorfix has developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample: Epitope Protection™ and AMFIA™, an ultra-sensitive dual-bead immunoassay.  Use of these technologies has generated a cerebrospinal fluid (CSF) screening test for both Alzheimer's disease (AD) and mild cognitive impairment (MCI), and an ultrasensitive method for detecting the hallmark of AD, aggregated beta-Amyloid, in brain tissue, CSF and blood from animal models of AD. For more information about Amorfix, visit www.amorfix.com.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.

ProMIS™, Epitope Protection™ and AMFIA™ are trademarks of Amorfix Life Sciences Ltd.

SOURCE: Amorfix Life Sciences Ltd.

Dr. Robert Gundel
President and Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: [phone]
Fax: [phone]
[email protected] 

Janet Clennett
Chief Financial Officer
Amorfix Life Sciences Ltd.
Tel: [phone]
Fax: [phone]
[email protected]